Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more
Hookipa Pharma Inc (HOOK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.249x
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has a cash flow conversion efficiency ratio of -0.249x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($28.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hookipa Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hookipa Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hookipa Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hookipa Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SAGA PURE ASA NK 1
F:SAT
|
N/A |
|
Tron Inc.
NASDAQ:TRON
|
-0.004x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
32.800x |
|
Telcon Inc
KQ:200230
|
0.004x |
|
DMS S.A. INH. EO 11845
F:DMS1
|
N/A |
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
-0.082x |
|
Eastern Platinum Limited
PINK:ELRFF
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Hookipa Pharma Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $51.21 Million | $-76.98 Million | -1.503x | -134.79% |
| 2023-12-31 | $89.86 Million | $-57.52 Million | -0.640x | -228.19% |
| 2022-12-31 | $102.52 Million | $-20.00 Million | -0.195x | +73.53% |
| 2021-12-31 | $89.59 Million | $-66.02 Million | -0.737x | -192.43% |
| 2020-12-31 | $156.12 Million | $-39.34 Million | -0.252x | +28.81% |
| 2019-12-31 | $117.90 Million | $-41.73 Million | -0.354x | -4.78% |
| 2018-12-31 | $44.40 Million | $-15.00 Million | -0.338x | -220.95% |
| 2017-12-31 | $-42.66 Million | $-11.91 Million | 0.279x | -- |